NEW YORK (GenomeWeb News) – Rosetta Genomics reported after the close of the market on Monday a sharp increase in revenues for the for the six-month period ended June 30, as the company expanded access to its suite of microRNA-based cancer diagnostics.

During the first half of 2013, Rosetta's revenues rose to $193,000 from $51,000 in the same period the year before.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.